Researchers from Peking Union Medical College Report New Studies and Findings in the Area of Takayasu's Arteritis (Serum Il-6 Level Trajectory for Predicting the Effectiveness and Safety of Tocilizumab In the Treatment of Refractory Takayasu...).

Researchers from Peking Union Medical College in Beijing, China have conducted a study on Takayasu's Arteritis, a cardiovascular disease. The study aimed to explore the value of monitoring serum interleukin-6 (IL-6) levels in predicting the effectiveness and safety of tocilizumab (TCZ) treatment in refractory Takayasu arteritis (TAK). The study found that the change in IL-6 levels after 6 months of TCZ treatment compared to the baseline can predict the overall treatment response at 12 months, 24 months, and sustained improvement. The study did not find a correlation between IL-6 dynamics and the occurrence of adverse events. [Extracted from the article]